Welcome to our dedicated page for Innoviva news (Ticker: INVA), a resource for investors and traders seeking the latest updates and insights on Innoviva stock.
Innoviva, Inc. (NASDAQ: INVA) is a diversified healthcare holding company whose news flow reflects its dual focus on royalty-based income and commercial-stage infectious disease and critical care therapies. Company announcements frequently highlight performance of its royalties portfolio tied to GSK respiratory products RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, alongside updates from Innoviva Specialty Therapeutics (IST), its critical care and infectious disease platform.
News releases from Innoviva and IST cover quarterly financial results, including royalty revenue and net product sales, as well as regulatory milestones and product launches. Examples include FDA acceptance and Priority Review of the New Drug Application for zoliflodacin, subsequent FDA approval of NUZOLVENCE® (zoliflodacin) for uncomplicated urogenital gonorrhea, and the U.S. launch of ZEVTERA® (ceftobiprole) for serious bacterial infections such as Staphylococcus aureus bloodstream infections, ABSSSI, and CABP.
Investors and healthcare professionals can also find coverage of clinical and scientific data presentations at major conferences like IDWeek, where Innoviva Specialty Therapeutics presents Phase 3 results, subgroup analyses, pharmacokinetic-pharmacodynamic studies, and microbiologic surveillance for agents including zoliflodacin, ZEVTERA, XACDURO®, and XERAVA®. Additional news items describe capital allocation decisions, such as share repurchase authorizations, strategic investments in healthcare companies, and licensing or acquisition of new platforms and assets.
This INVA news page aggregates these updates in one place, making it easier to track earnings announcements, regulatory decisions, conference presentations, and portfolio developments. Readers interested in Innoviva’s evolving role in respiratory royalties, antibiotic development, and critical care therapeutics can use this feed to monitor key events and company disclosures over time.
Innoviva Specialty Therapeutics (NASDAQ: INVA) announced that its two antimicrobial therapies, ZEVTERA® and XACDURO®, have been nominated for the 2025 Prix Galien USA "Best Pharmaceutical Product" Award, often considered the Nobel Prize equivalent in biopharmaceutical research.
ZEVTERA, FDA-approved in April 2024, is the first advanced-generation cephalosporin approved for Staphylococcus aureus bloodstream infections, including MRSA strains. XACDURO, approved in May 2023, is the first and only antibiotic approved for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter.
The company is also awaiting FDA decision on zoliflodacin, an investigational therapy for uncomplicated gonorrhea, expected by end of 2025.
Innoviva (NASDAQ: INVA) reported strong Q2 2025 financial results, with total royalty revenue of $67.3 million from GSK and net product sales of $35.5 million. The company achieved net income of $63.7 million ($1.01 per share), compared to a net loss in Q2 2024.
Key highlights include the U.S. launch of ZEVTERA, their fourth product and first FDA-approved cephalosporin for MRSA-related bacteremia. Additionally, the FDA accepted the NDA for zoliflodacin with Priority Review, setting a PDUFA date of December 15, 2025. U.S. net product sales showed impressive growth of 54% year-over-year, led by GIAPREZA ($17.0M) and XACDURO ($8.5M).
The company maintains a strong financial position with $397.5 million in cash and cash equivalents, plus $88.3 million in receivables as of June 30, 2025.
Armata Pharmaceuticals (NYSE American: ARMP) has secured a $10 million credit agreement with Innoviva Strategic Opportunities , its largest shareholder. The loan facility comes with a 14.0% annual interest rate and matures on March 12, 2026.
The proceeds will support the development of Armata's lead therapeutic phage candidates: AP-PA02 targeting Pseudomonas aeruginosa infections and AP-SA02 for Staphylococcus aureus infections. The funding will specifically enable the company to complete its Phase 1b/2a trial in acute Staphylococcus aureus bacteremia and prepare for an end-of-Phase 2 FDA meeting.
Additionally, Armata amended three existing credit agreements with Innoviva, extending their maturity dates to March 12, 2026. The company continues to seek additional funding sources, including non-dilutive options, to support late-stage clinical trials.
Innoviva (NASDAQ: INVA), a diversified holding company, has announced its participation in the Barclays 27th Annual Global Healthcare Conference in Miami, FL. CEO Pavel Raifeld will engage in a fireside chat on Tuesday, March 11, 2025, at 8:30 a.m. Eastern Time.
The company, which maintains a core royalties portfolio and operates the Innoviva Specialty Therapeutics (IST) platform focusing on critical care and infectious diseases, will provide a live webcast of the presentation. Investors can access the webcast through the Investor Relations section of Innoviva's website under 'Events & Presentations' at investor.inva.com/presentations-events. The presentation recording will remain available for replay for 90 days after the event.
Innoviva (NASDAQ: INVA) reported strong financial results for Q4 and full year 2024. GSK royalties reached $66.0M in Q4 and $255.6M for the full year. The company's Specialty Therapeutics division achieved significant growth with U.S. net product sales of $24.9M in Q4 and $80.9M for 2024, representing 47% year-over-year growth.
Q4 net income was $20.3M ($0.32 per share), while full-year net income reached $23.4M ($0.37 per share). The company ended 2024 with $305.0M in cash and $86.4M in receivables.
Key developments include acquiring U.S. rights to ZEVTERA®, planning for mid-2025 launch, and positive Phase 3 data for zoliflodacin. Product performance showed strong results: GIAPREZA® ($53.4M), XERAVA® ($12.8M), and XACDURO® ($14.7M) in annual U.S. sales. The company forecasts U.S. net product sales to exceed $100M in 2025.